RT Journal Article
T1 Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis
A1 Lopez-Beltran, Antonio
A1 Blanca, Ana
A1 Cimadamore, Alessia
A1 Gogna, Rajan
A1 Montironi, Rodolfo
A1 Cheng, Liang
K1 bladder cancer
K1 molecular taxonomy
K1 molecular
K1 classification
K1 NanoString
K1 luminal
K1 basal
K1 Cancer
K1 Subtypes
K1 Identification
K1 Signature
K1 Cisplatin
K1 Outcomes
K1 Basal
AB Simple SummaryOur study aimed to apply a quantitative method based on mRNA counting as nCounter (NanoString Technologies, Inc). This method can obtain precise and accurate measures of RNA expression compared to RT-PCR, and which might represent an alternative to the NGS-genomic/transcriptomic profiling frequently used to generate molecular data in bladder cancer and provide clinically meaningful datasets for the molecular classification of bladder cancer. The current study generated a four-gene classifier, incorporating GATA3 and KRT20 (typically related to luminal molecular subtype) and KRT5 and KRT14 (typically related to basal molecular subtype). This methodology allowed us to explore differences in clinicopathologic parameters and potential sensitivities to ICI immunotherapy in a cohort series of 91 urothelial carcinomas of the bladder.Molecular classification of bladder carcinoma is a relevant topic in modern bladder cancer oncology due to its potential to improve oncological outcomes. The available molecular classifications are generally based on transcriptomic profiles, generating highly diverse categories with limited correlation. Implementation of molecular classification in practice is typically limited due to the high complexity of the required technology, the elevated costs, and the limited availability of this technology worldwide. We have conducted a gene expression analysis using a four-gene panel related to luminal and basal subtypes in a series of 91 bladder cancer cases. NanoString-based gene expression analysis using typically luminal (GATA3+/KRT20+) and basal markers (KRT14+/KRT5+/GATA3low/-/KRT20low/-) classified urothelial bladder carcinoma samples as luminal, basal, and a third category (KRT14-/KRT5-/GATA3-/KRT20-), null/double negative (non-luminal/non-basal). These three categories were meaningful in terms of overall cancer-specific survival (p
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/25620
UL https://hdl.handle.net/10668/25620
LA en
DS RISalud
RD Apr 8, 2025